Equity Research on Allergan Inc. and Teva Pharmaceutical Industries Ltd - Generic Releases and Good

Equity Research on Allergan Inc. and Teva Pharmaceutical Industries Ltd - Generic Releases and Good Times for Drug Manufacturers

ID: 160426

(firmenpresse) - NEW YORK, NY -- (Marketwire) -- 06/27/12 -- has a handpicked team of market professionals with over 100 years of combined investing experience. Today they are providing members comprehensive research on the Drug Manufacturers - Other industry and are offering free analytical research on (NYSE: AGN) and (NYSE: TEVA). Register with us now to have free access to these research reports. Simply click on the link below.



The drug manufacturers - other industry has been awash in news as of late. Several companies have recently reported their quarterly earnings, while others have been releasing new generic versions of products. Court cases have also been plentiful, and could have serious effects on those involved. Get your free reports on and at . There is no commitment to join.

ShinesRooms.com is the Ultimate Trading Environment for investors. If you are considering owning Allergan Inc. and Teva Pharmaceutical Industries Limited then you should sign up for a free membership and our complimentary reports today. Over the last 5 years our returns outpaced any of the major indexes. Sign up today by clicking on the link below to find out what you are missing.



The industry as a whole is performing well though, as a recovering economy back home and a broad array of products have helped many through the tricky economic times. Allergan Inc. had a solid 1st quarter, as its diluted earnings per share and total product net sales increased over the same period last year. report is accessible for free by registering today at



One company that has been releasing a number of new products recently is Teva Pharmaceutical Industries Limited. Teva UK, part of Teva Pharmaceuticals, newly launched Rivastigmine capsules, its generic version of Exelon®, a Novartis drug used among other things for the treatment of Alzheimer's dementia. Teva has also recently launched Olanzapine and Fluoxetine Capsules, a generic equivalent of Symbyax®. report is accessible for free by registering today at







The two stocks research reports are available for free by signing up now on the link below.





Shine's Rooms is the brain child of David Shine, a 13 year Wall Street veteran with a stellar track record. For 13 years Shine has trained thousands of traders to navigate and profit from the markets. Using cutting edge technology, Shine provides you with a community in which you can trade alongside Shine and his Team as they guide you through the market's ever-changing landscape.

To view our visit this link .






Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  T3Media Launches Paya.com, a Next Generation Digital Content Commerce Service PivotLink and ChatterPlug Improve Visibility Into Retail Customer Engagement
Bereitgestellt von Benutzer: MARKETWIRE
Datum: 27.06.2012 - 12:00 Uhr
Sprache: Deutsch
News-ID 160426
Anzahl Zeichen: 0

contact information:
Town:

NEW YORK, NY



Kategorie:

Venture Capital



Diese Pressemitteilung wurde bisher 243 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Equity Research on Allergan Inc. and Teva Pharmaceutical Industries Ltd - Generic Releases and Good Times for Drug Manufacturers"
steht unter der journalistisch-redaktionellen Verantwortung von

Shinesrooms.com (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Shinesrooms.com



 

Werbung



Facebook

Sponsoren

foodir.org The food directory für Deutschland
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z